Table 2.
Plasma Hcy levels in patients with anti–NMDAR encephalitis.
| Variables | Value (μmol/L) | Range (min–max, μmol/L) | P* value |
|---|---|---|---|
| GENDER | |||
| Male (IQR, n = 23) | 11.80 (9.49–16.05) | 6.36–19.97 | |
| Female (IQR, n = 22) | 8.33 (6.59–10.90) | 3.74–17.41 | 0.001P2 |
| AGE | |||
| <18 y (IQR, n = 10) | 9.90 (7.49–11.65) | 3.80–15.35 | |
| ≥18 y (IQR, n = 35) | 9.64 (7.32–13.91) | 3.74–19.97 | 0.401P2 |
| mRS | |||
| <4 (IQR, n = 16) | 10.45 (7.82–13.53) | 3.80–17.37 | |
| ≥4 (IQR, n = 29) | 9.49 (7.24–12.06) | 3.74–19.97 | 0.975P2 |
| DISEASE DURATION (d) | |||
| >30 (mean ±SD, n = 19) | 11.11 ± 5.26 | 3.74–19.97 | |
| ≤30 (mean ±SD, n = 26) | 10.30 ± 3.18 | 5.93–18.86 | 0.557P1 |
| BRAIN MRI | |||
| Normal (mean ±SD, n = 25) | 10.12 ± 5.02 | 3.74–17.55 | |
| Abnormal (mean ±SD, n = 20) | 11.30 ± 5.02 | 3.80–19.97 | 0.373P1 |
| TUMOR | |||
| With (mean ±SD, n = 9) | 9.76 ± 4.61 | 3.74–19.97 | |
| Without (mean ±SD, n = 36) | 10.87 ± 4.07 | 3.80–19.9 | 0.482P1 |
| SEIZURE | |||
| With (mean ±SD, n = 35) | 11.32 ± 4.36 | 3.74–19.97 | |
| Without (mean ±SD, n = 10) | 8.29 ± 2.15 | 3.80–11.55 | 0.005P1 |
Anti-NMDAR, anti-N-Methyl-D-aspartate receptor; Hcy, homocysteine; mRS, modified Rankin Scale; SD, standard deviation, IQR, interquartile range.
*
All continuous variables were presented as the mean ( ± standard deviation) if the data was normally distributed or as median values and quartiles if the data was not normally distributed. To assess the significance of differences between groups, the Student's t test was applied when the data were normally distributed, while Mann–Whitney U tests were performed when the data were not normally distributed. P* value: P1, the Student's t-test; P2, Mann–Whitney U tests.